130 related articles for article (PubMed ID: 37558588)
21. Hemoglobin-platelet index as a prognostic factor in patients with peripheral T-cell lymphoma.
Yagi Y; Kanemasa Y; Sasaki Y; Okumura S; Watanabe T; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Morita Y; Tamura T; Nakamura S; Okuya T; Shimoyama T
EJHaem; 2023 Aug; 4(3):656-666. PubMed ID: 37601871
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome.
Yang DH; Kim WS; Kim SJ; Bae SH; Kim SH; Kim IH; Yoon SS; Mun YC; Shin HJ; Chae YS; Kwak JY; Kim H; Kim MK; Kim JS; Won JH; Lee JJ; Suh CW
Biol Blood Marrow Transplant; 2009 Jan; 15(1):118-25. PubMed ID: 19135950
[TBL] [Abstract][Full Text] [Related]
23. The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: A single-institution analysis of 240 Chinese patients.
Chen H; Tao Y; Zhou Y; Liu P; Yang J; He X; Zhou S; Qin Y; Song Y; Gui L; Zhang C; Yang S; Shi Y
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e202-e214. PubMed ID: 35821612
[TBL] [Abstract][Full Text] [Related]
24. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.
Niitsu N; Okamoto M; Nakamine H; Aoki S; Motomura S; Hirano M
Hematol Oncol; 2008 Sep; 26(3):152-8. PubMed ID: 18395866
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL).
Cottereau AS; Becker S; Broussais F; Casasnovas O; Kanoun S; Roques M; Charrier N; Bertrand S; Delarue R; Bonnet C; Hustinx R; Gaulard P; de Leval L; Vera P; Itti E; Mounier N; Haioun C; Tilly H; Meignan M
Ann Oncol; 2016 Apr; 27(4):719-24. PubMed ID: 26787236
[TBL] [Abstract][Full Text] [Related]
26. The Expressions of P53, Bcl-2, and P-Glycoprotein and Prognostic Impact in Patients with Peripheral T-Cell Lymphoma (PTCL).
Julamanee J; Kayasut K; Lekhakula A
J Med Assoc Thai; 2015 Oct; 98(10):950-6. PubMed ID: 26638586
[TBL] [Abstract][Full Text] [Related]
27. Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study.
Martín García-Sancho A; Rodríguez-Pinilla SM; Domingo-Domenech E; Climent F; Sánchez-Garcia J; López Jiménez J; García-Cosío Piqueras M; Castellvi J; González AJ; González de Villambrosia S; Gómez Codina J; Navarro B; Rodríguez G; Borrero JJ; Fraga M; Naves A; Baeza L; Córdoba R
Br J Haematol; 2023 Oct; 203(2):182-193. PubMed ID: 37386897
[TBL] [Abstract][Full Text] [Related]
28. Pooled analysis of pralatrexate single-agent studies in patients with relapsed/refractory peripheral T-cell lymphoma.
O'Connor OA; Ko BS; Wang MC; Maruyama D; Song Y; Yeoh EM; Manamley N; Tobinai K
Blood Adv; 2024 Jun; 8(11):2601-2611. PubMed ID: 38429077
[TBL] [Abstract][Full Text] [Related]
29. Chidamide Maintenance Therapy Following Induction Therapy in Patients With Peripheral T-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Case Series From China.
Guo W; Wang X; Li J; Yin X; Zhao Y; Tang Y; Wang A; Bai O
Front Oncol; 2022; 12():875469. PubMed ID: 35747802
[TBL] [Abstract][Full Text] [Related]
30. Serum concentrations of l-kynurenine predict clinical outcomes of patients with peripheral T-cell lymphoma, not otherwise specified.
Shibata Y; Hara T; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Goto N; Nannya Y; Ito H; Kito Y; Miyazaki T; Takeuchi T; Saito K; Seishima M; Takami T; Moriwaki H; Shimizu M; Tsurumi H
Hematol Oncol; 2017 Dec; 35(4):637-644. PubMed ID: 27338762
[TBL] [Abstract][Full Text] [Related]
31. Comparison of four prognostic scores in peripheral T-cell lymphoma.
Gutiérrez-García G; García-Herrera A; Cardesa T; Martínez A; Villamor N; Ghita G; Martínez-Trillos A; Colomo L; Setoain X; Rodríguez S; Giné E; Campo E; López-Guillermo A
Ann Oncol; 2011 Feb; 22(2):397-404. PubMed ID: 20631009
[TBL] [Abstract][Full Text] [Related]
32. The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores.
Huh SJ; Oh SY; Lee S; Lee JH; Kim SH; Lee GW; Kim SJ; Kim WS; Lee HS; Jo JC; Kim MJ; Kwon JH; Kim HJ
Int J Hematol; 2019 Oct; 110(4):438-446. PubMed ID: 31250282
[TBL] [Abstract][Full Text] [Related]
33. High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study.
Morita-Fujita M; Katoh D; Shimomura Y; Ishikawa T
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e337-e342. PubMed ID: 31053551
[TBL] [Abstract][Full Text] [Related]
34. 25-Hydroxy vitamin D deficiency is an inferior predictor of peripheral T-cell lymphomas.
Shen HR; Tang J; Li WY; Liang JH; Li Y; Wu JZ; Wang L; Li JY; Gao R; Yin H; Xu W
Ann Hematol; 2024 Feb; 103(2):565-574. PubMed ID: 37951853
[TBL] [Abstract][Full Text] [Related]
35. Peripheral T-Cell Lymphoma, not Otherwise Specified (PTCL-NOS).
Oluwasanjo A; Kartan S; Johnson W; Alpdogan O; Gru A; Mishra A; Haverkos BM; Gong J; Porcu P
Cancer Treat Res; 2019; 176():83-98. PubMed ID: 30596214
[TBL] [Abstract][Full Text] [Related]
36. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network.
Federico M; Bellei M; Marcheselli L; Schwartz M; Manni M; Tarantino V; Pileri S; Ko YH; Cabrera ME; Horwitz S; Kim WS; Shustov A; Foss FM; Nagler A; Carson K; Pinter-Brown LC; Montoto S; Spina M; Feldman TA; Lechowicz MJ; Smith SM; Lansigan F; Gabus R; Vose JM; Advani RH;
Br J Haematol; 2018 Jun; 181(6):760-769. PubMed ID: 29672827
[TBL] [Abstract][Full Text] [Related]
37. Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404).
Cho H; Yoon DH; Shin DY; Koh Y; Yoon SS; Kim SJ; Do YR; Lee GW; Kwak JY; Park Y; Kim MK; Kang HJ; Yi JH; Yoo KH; Lee WS; Park BB; Jo JC; Eom HS; Kim HJ; Jeong SH; Won YW; Sohn BS; Kwon JH; Suh C; Kim WS
Cancer Res Treat; 2023 Apr; 55(2):684-692. PubMed ID: 36596727
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance and predictive risk factors for event-free survival at 24 months in patients with PTCL, NOS.
Cao Z; Wang X; Xue X; Feng X
Ann Hematol; 2024 Mar; 103(3):869-883. PubMed ID: 38040859
[TBL] [Abstract][Full Text] [Related]
39. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
40. Survival of Subcutaneous Panniculitis-Like T-Cell Lymphoma and Peripheral T-Cell Lymphoma Not Otherwise Specified: A Propensity-Matched Analysis of the Surveillance, Epidemiology, and End Results Database.
Bhatt VR; Giri S; Verma V; Manandhar S; Pathak R; Bociek RG; Vose JM; Armitage JO
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):373-8. PubMed ID: 27349764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
